A simulation platform to predict dose and therapeutic window of immunocytokines
预测免疫细胞因子剂量和治疗窗的模拟平台
基本信息
- 批准号:10698708
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAddressAffinityAnti-CEA AntibodyAnti-Inflammatory AgentsAntibodiesAreaAutoimmune DiseasesAvidityBenchmarkingBindingBiological AssayBiological MarkersBiological ProductsCD8B1 geneCalibrationCell CountCellsCharacteristicsChimeric ProteinsClinicClinicalClinical DataClinical TrialsClinical Trials DesignCommunicationCytokine ReceptorsDataDevelopmentDiseaseDisparateDoseDose LimitingDrug KineticsEquilibriumEragrostisEvaluationFlow CytometryFosteringHalf-LifeHealthcareHumanImmuneImmune TargetingImmune responseImmunotherapyIn VitroInflammatoryInflammatory ResponseInterleukin-10Interleukin-12Interleukin-15Interleukin-2Interleukin-4KineticsLeadLinkMalignant NeoplasmsMarketingMeasurableMeasurementMediatingModelingMolecularNatural Killer CellsOncologyOnline SystemsParameter EstimationPatientsPharmaceutical PreparationsPharmacodynamicsPharmacologyPhasePopulationProcessProtein EngineeringPsoriasisRecombinant CytokinesRegimenRegulatory T-LymphocyteReportingRheumatoid ArthritisRiskRunningScanningSelection CriteriaSerumSmall Business Innovation Research GrantSpecificityStructureSystemTestingTherapeuticTimeTissuesToxic effectantibody conjugatearmcancer therapycandidate selectioncell growthcell typeclinical applicationclinical efficacyclinical predictorscohortcommercializationcomputational platformcostcytokinecytokine therapydesigndrug developmentdrug dispositioneffector T cellgraphical user interfacehigh riskimmune activationin silicoin vivointeractive toollead candidatemodels and simulationmultidisciplinarynext generationnovelnovel strategiesnovel therapeuticspharmacokinetics and pharmacodynamicspre-clinicalpredicting responsepredictive modelingreceptorscreeningsimulationsystemic toxicitytooltranslational approachvirtual patientweb app
项目摘要
Project Summary/Abstract
Immunocytokines (ICs) are fusion proteins of an engineered cytokine conjugated to an antibody. These novel molecules
are the next generation of cytokine-based immunotherapies with potential applications in a diverse range of diseases such
as rheumatoid arthritis (RA), psoriasis, and cancer. ICs are designed to selectively target diseased tissue or specific
immune cells with minimal systemic immune activation that typically leads to dose-limiting toxicity in recombinant
cytokine therapy. However, it is challenging to design a molecule with high target specificity, predict its pharmacokinetics
and identify doses that achieve high efficacy but low toxicity, i.e. the therapeutic window.
We are proposing to develop a simulation platform for IC screening that will computationally predict dose and therapeutic
window of novel ICs under development. The platform will implement a quantitative systems pharmacology (QSP) model
that mechanistically describes the binding of an IC to target and off-target cells and links cytokine receptor occupancy to
cellular activation and expansion dynamics. The model will predict in vivo pharmacokinetics (PK) and pharmacodynamics
(PD) for an input dose and dosing regimen of a proposed IC. Simulations will report readouts such as cell counts and
soluble cytokine levels that are clinically observable biomarkers of efficacy and toxicity. The model will be general
enough to simulate pro- and anti-inflammatory ICs. A modular design will allow us to add new cell types and
cytokines/receptors as needed to adequately model the crosstalk between the inflammatory and regulatory arms of the
immune response.
In Phase I of this Fast Track proposal, we will demonstrate the technical feasibility of developing a single mechanistic
QSP model structure that captures drug dose- dependent expansion and contraction of four unique IC molecules. By
fitting preclinical and clinical data for each molecule, we will establish a robust translational strategy for human dose
prediction. In Phase II the platform model will be integrated with and made accessible through Applied BioMath’s
Assess™ browser-based interface. With this setup, users can interactively explore the IC design space and use simulations
to understand the impact of varying dose, dosing interval, target affinities, cytokine potency and drug half-life on clinical
PK/PD. We expect that this interactive tool will foster effective communication within multidisciplinary drug
development teams, and help them rationally identify optimal molecular characteristics and dosing strategies for novel
ICs. The platform will also allow virtual patient cohort simulations to guide selection criteria for clinical trials.
There are currently no effective tools to screen candidate molecules in the IC space. Our proposed computational platform
to predict the optimal dose and therapeutic window of novel ICs will accelerate the lengthy and expensive lead candidate
selection process, and thus lower the cost of IC development, facilitate clinical trial design, reduce late stage attrition and
bring new drugs to the market faster to benefit patient healthcare.
项目总结/摘要
免疫细胞因子(IC)是工程化细胞因子与抗体缀合的融合蛋白。这些新颖的分子
是下一代基于精氨酸的免疫疗法,具有在多种疾病中的潜在应用,
如类风湿性关节炎(RA)、牛皮癣和癌症。IC被设计为选择性地靶向患病组织或特定的
具有最小全身免疫活化的免疫细胞,其通常导致重组体中的剂量限制性毒性,
细胞因子疗法然而,设计具有高靶向性的分子,预测其药代动力学,
并确定实现高功效但低毒性的剂量,即治疗窗。
我们建议开发一个IC筛查的模拟平台,该平台将通过计算预测剂量和治疗效果。
开发中的新型IC的窗口。该平台将实施定量系统药理学(QSP)模型
其在机制上描述了IC与靶细胞和脱靶细胞的结合,并将细胞因子受体占有率与
细胞活化和扩张动力学。该模型将预测体内药代动力学(PK)和药效学
(PD)输入剂量和拟定IC的给药方案。模拟将报告读数,如细胞计数和
可溶性细胞因子水平是临床上可观察到的功效和毒性的生物标志物。该模型将是通用的
足以模拟促炎和抗炎IC模块化设计将允许我们添加新的细胞类型,
细胞因子/受体,以充分模拟炎症和调节臂之间的串扰。
免疫反应
在这个快速通道建议的第一阶段,我们将证明开发一个单一机制的技术可行性。
QSP模型结构,捕获药物剂量依赖性的膨胀和收缩的四个独特的IC分子。通过
拟合每个分子的临床前和临床数据,我们将建立一个强大的人类剂量转化策略,
预测.在第二阶段,平台模型将与Applied BioMath的
Assess™基于浏览器的界面。通过此设置,用户可以交互式地探索IC设计空间并使用仿真
了解不同剂量、给药间隔、靶亲和力、细胞因子效力和药物半衰期对临床
PK/PD。我们希望这种互动工具将促进多学科药物管理系统内的有效沟通。
开发团队,并帮助他们合理地确定最佳的分子特征和剂量策略,
IC。该平台还将允许虚拟患者队列模拟,以指导临床试验的选择标准。
目前还没有有效的工具来筛选IC空间中的候选分子。我们提出的计算平台
预测新型IC的最佳剂量和治疗窗口将加速冗长而昂贵的先导候选药物的开发,
选择过程,从而降低IC开发成本,促进临床试验设计,减少后期流失,
更快地将新药推向市场,使患者的医疗保健受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raibatak Das其他文献
Raibatak Das的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant